Stocks Comparison
Guardian Pharmacy Services vs Petmed Express: revenue, profit, margins and growth compared
Guardian Pharmacy Services brought in $1.4B of revenue in fiscal 2025, Petmed Express $179M in fiscal 2026. Revenue changed by +17.9% at Guardian Pharmacy Services and -21.1% at Petmed Express on the year before, so Guardian Pharmacy Services grew faster. Guardian Pharmacy Services kept 3.4% of its revenue as net profit, Petmed Express -32.0%. Free cash flow was $86.8M at Guardian Pharmacy Services and -$33M at Petmed Express.
Side by side, latest fiscal year
| GRDN | PETS | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2026 (March 31, 2026) |
| Revenue | $1.4B | $179M |
| Revenue growth | +17.9% | -21.1% |
| Net income | $49.2M | -$57.3M |
| Net margin | 3.4% | -32.0% |
| Free cash flow | $86.8M | -$33M |
| Free cash flow margin | 6.0% | -18.4% |
| Earnings per share (diluted) | n/a | -$2.74 |
| Cash | $65.6M | $21.4M |
| Debt | $0 | n/a |
| Price to earnings | n/a | n/a |
| Market value | $2.6B | $33.2M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #53 of 93 · Consumer staples | #76 of 93 · Consumer staples |
Over the years
Questions about Guardian Pharmacy Services and Petmed Express
Which is bigger by revenue, Guardian Pharmacy Services or Petmed Express?
Guardian Pharmacy Services is bigger by revenue: $1.4B in fiscal 2025, against $179M for Petmed Express in fiscal 2026.
Which keeps more of its revenue as profit, Guardian Pharmacy Services or Petmed Express?
Guardian Pharmacy Services had a net margin of 3.4% in fiscal 2025; Petmed Express had -32.0% in fiscal 2026.
Which grew revenue faster, Guardian Pharmacy Services or Petmed Express?
In their latest fiscal years revenue changed by +17.9% at Guardian Pharmacy Services and -21.1% at Petmed Express.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.